Check for updates

OPEN ACCESS

EDITED BY Mauro Serafini, University of Teramo, Italy

REVIEWED BY Alexander E. Berezin, Paracelsus Medical University, Austria Duo Rui Nie, Hunan University of Chinese Medicine, China

*CORRESPONDENCE Qingquan Chen ⊠ 2210220170@fjmu.edu.cn Jing Huang ⊠ j_huang1@outlook.com

[†]These authors have contributed equally to this work

RECEIVED 02 May 2024 ACCEPTED 10 September 2024 PUBLISHED 20 September 2024

CITATION

Chen C, Lin Y, Xu J, Chen Q and Huang J (2024) Causal relationship between green tea intake and gastrointestinal disorders: a two-sample Mendelian randomization study. *Front. Nutr.* 11:1426779. doi: 10.3389/fnut.2024.1426779

COPYRIGHT

these terms.

© 2024 Chen, Lin, Xu, Chen and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with

Causal relationship between green tea intake and gastrointestinal disorders: a two-sample Mendelian randomization study

Chan Chen^{1†}, Yifei Lin^{2†}, Jinni Xu², Qingquan Chen^{2*} and Jing Huang^{1*}

¹Fujian Vocational College of Agricultural, Fuzhou, China, ²Fujian Medical University, Fuzhou, China

Background: The precise association between green tea intake and gastrointestinal disorders remains controversial. This study aimed to investigate the potential causal association between green tea intake and gastrointestinal disorders through a two-sample Mendelian randomization (MR) study.

Methods: Utilizing publicly accessible data from genome-wide association studies (GWAS), we identified SNPs strongly linked with the study variables from multiple large databases to serve as instrumental variables (IVs). MR analyses were executed utilizing the inverse variance weighting (IVW) method, with the resultant effect estimates serving as the primary outcome measure. In addition, a multivariate MR design was performed to adjust for smoking and alcohol consumption. To ensure the robustness of our findings, a series of sensitivity analyses were conducted to assess reliability.

Results: Univariable MR analysis revealed suggestive associations between green tea intake and gastroesophageal reflux (OR = 0.9950, 95% CI 0.9900–1.0000, $p_{IVW} = 0.047$), diverticulosis (OR = 0.9998, 95% CI 0.9996–1.0000, $p_{IVW} = 0.030$), Crohn's disease (OR = 1.0001, 95% CI 1.0000–1.0002, $p_{IVW} = 0.019$), and cholangitis was observed (OR = 1.0440, 95% CI 1.0100–1.0790, $p_{IVW} = 0.011$). Multivariate MR analysis indicated after controlling for potential confounders, greater green tea consumption was suggestively associated with the decreased risk of oesophagitis (OR = 0.9667, 95% CI: 0.9405–0.9936, $p_{IVW} = 0.016$) and gastric cancer (OR = 0.9810, 95% CI: 0.9628–0.9996, $p_{IVW} = 0.046$). Nevertheless, multivariate MR analysis also showed that greater green tea consumption was suggestively associated with the increased risk of Crohn's disease (OR = 1.0001, 95% CI: 1.0000–1.0002, $p_{IVW} = 0.007$). Sensitivity analyses confirmed that these results were reliable.

Conclusion: Our study provides suggestive evidence that genetically predicted green tea intake is causally associated with the risk of oesophagitis, gastric cancer and Crohn's disease, but a larger GWAS database is needed for validation.

KEYWORDS

green tea intake, Mendelian randomization, gastrointestinal disorders, association study, causal relationship

Introduction

Gastrointestinal disorders afflict a significant portion of the population, with approximately 50 million visits yearly recorded for such conditions (1, 2). As highlighted by Peery et al. (3), these disorders lead to millions of healthcare encounters and hundreds of thousands of deaths annually in the United States, incurring billions of dollars in costs. This category encompasses a diverse array of conditions, including gastroesophageal reflux disease (GERD), diverticular disease, Crohn's disease, and cholangitis. Gastroesophageal reflux disease (GERD) stands out as one of the most prevalent gastrointestinal disorders, often linked to lifestyle and dietary factors (4). It has also been suggested that beverage consumption may be a potential risk factor for gastroesophageal reflux disease (GERD) in young adults (5).

Meanwhile, diverticulosis, a prevalent condition, is increasingly prevalent in Western societies (6), with dietary habits identified as a contributing risk factor for its complications (7). Crohn's disease (CD) triggers chronic inflammation within the gastrointestinal tract (8), often leading to malnutrition and heightened morbidity and mortality (9). Additionally, cholangitis, characterized by life-threatening biliary infection, exhibits mortality rates nearing 100% (10). Hence, investigating the potential link between beverage consumption patterns and gastrointestinal disorders holds paramount importance for our everyday health. Tea ranks among the most widely consumed beverages globally and is rich in catechins, natural polyphenolic phytochemicals renowned for their potent antioxidant properties (11, 12). Catechins play a pivotal role in mitigating oxidative stress by effectively inhibiting its excess and facilitating the activation of key antioxidants like glutathione peroxidase (GPO) and glutathione (GSH), thereby curbing oxidative damage within the gastrointestinal tract (12).

Numerous studies have shown that tea consumption may be closely linked to non-malignant digestive diseases (13). For instance, excessive consumption of green tea could pose a risk factor for gastroesophageal reflux disease (GERD) (13), while tea intake appears to have a negative association with the risk of Crohn's disease (14). Additionally, longterm green tea consumption has demonstrated a preventive effect by reducing the risk of gastric and colorectal cancers (15, 16). Nevertheless, the precise causal relationship between green tea consumption and gastrointestinal diseases remains elusive. Furthermore, limitations such as small sample sizes and potential biases in study population selection may hinder the generalizability of certain findings. Moreover, traditional observational studies often struggle to address the challenges posed by reverse causality and confounding factors.

Mendelian randomization (MR) represents a form of instrumental variable analysis that leverages genetic variations as instrumental variables. MR is a type of instrumental variable analysis, which uses genetic variation as an instrumental variable to measure the association between genetic variation and exposure factors, between genetic variation and disease outcome, and then infer the association between exposure factors and disease outcome, and accordingly explore the causal relationship between exposure and outcome (17). In this study, we intend to investigate the causal relationship between green tea consumption as the exposure and gastrointestinal diseases as the outcome through two-sample Mendelian randomization. Additionally, we aim to explore the varying effects of green tea consumption across different gastrointestinal conditions, to offer novel insights into gastrointestinal disease surveillance and preventive strategies for green tea-consuming populations.

Methods

Mendelian randomization study design

MR analysis relies on three fundamental assumptions. Firstly, genetic variants employed as instrumental variables must exhibit robust associations with the exposure under investigation. Secondly, the selected genetic variant should not be linked to any confounding factors. Lastly, the chosen genetic variants should solely influence the risk of the outcome through relevant risk factors (Figure 1). In addition, considering the genetic association of green tea consumption with smoking behavior and alcohol consumption, we further used a multivariate MR design to systematically minimize pleiotropy for both traits. To adhere to ethical guidelines, all original GWAS utilized in this research underwent review and approval by respective institutional review boards. Furthermore, given that this study constitutes a reanalysis of previously collected and published data, no additional ethical approval was deemed necessary.

Data sources

The pooled data utilized in our study were sourced from genomewide association studies (GWASs) conducted in European-descent participants from large-scale consortia or studies. For the exposure data, the SNPs associated with green tea intake were identified from 64,949 individuals from UKBiobank. In the original study, green tea intake was assessed as a categorical ordered variable (cups of green tea), with the original questionnaire categorizing tea consumption into 0, 1, 2, 3, 4, 5, and \geq 6 cups and each cup corresponds to 250 mL (data field: 100420). For the outcome data, we included 25 gastrointestinal diseases covering upper gastrointestinal diseases, lower gastrointestinal diseases, hepatobiliary and pancreatic diseases, and acute appendicitis. Among them, data for Crohn's disease and intestinal obstruction were obtained from UKBiobank. The outcome data for hiatus hernia and diverticular disease were obtained from the study of Dönertaş et al. (18). The study of Fairfield et al. (19) provided us with GWAS data for non-alcoholic fatty liver disease. The data of oesophagitis, gastroduodenal ulcer, acute gastritis, chronic gastritis, irritable bowel syndrome, alcoholic liver disease, cholecystitis, cholelithiasis, acute pancreatitis, chronic pancreatitis, and acute appendicitis were from FinnGen database. Gastroesophageal reflux, esophageal cancer, gastric ulcer, gastric cancer, ulcerative colitis, colorectal cancer, cirrhosis, and pancreatic cancer were obtained from the study of Sakaue et al. (20). The outcome data for cholangitis were obtained from the study of Ji et al. (21). Supplementary Table S2 shows the specifics of the GWAS pooled databases employed in our analysis. Details regarding ethical approval and participant informed consent for the GWASs are available in the respective GWAS publications referenced within the manuscript.

Selection of genetic instruments

During the data extraction phase, single nucleotide polymorphisms (SNPs) from the GWAS data were selected as instrumental variables



based on their association with the study factors ($p < 5 \times 10^{-8}$). Subsequently, SNPs exhibiting linkage disequilibrium were filtered out, employing a correlation threshold parameter set at $r^2 \le 0.001$ and kb $\le 10,000$. No SNPs associated with potential confounding factors such as smoking initiation and alcohol consumption were identified by the NHGRI-EBI Catalog databases¹ and LDtrait tool² (22). Ultimately, we identified 21 SNPs significantly linked to green tea intake. Supplementary Table S3 presents the *F*-statistics associated with these SNPs, all of which exceeded 10, thereby ensuring the exclusion of weak instrumental variables and affirming the robust correlation between the instrumental variables and all exposures.

Two-sample Mendelian randomization analysis

We conducted a two-sample MR analysis to investigate the association between green tea intake and gastrointestinal disorders. The primary MR method employed was inverse-variance weighting (IVW). This method is a standard approach for aggregating MR data, enabling the direct estimation of causal relationships among study subjects through aggregated data (23). Outliers in the IVW linear regression were identified using the Mendelian Randomization of Multiple Phenotype Residual Sums and Outliers (MR-PRESSO) method, and MR estimates were adjusted following outlier removal. Additional complementary methods included IVW (fixed effects), weighted median, weighted mode, and simple mode (Figure 1). Median methods, which necessitate that at least half of the genetic instruments in the pooled data are valid to attain a consistent effect value, encompass unweighted median (simple median), weighted median, and penalized weighted median estimation.

Among these, the weighted median combines weighted estimation and median, allowing for the accurate assessment of each genetic variant's evaluated value based on different causal effect weights (24, 25). Furthermore, if the IVW method yields statistical significance while the other methods do not, the odds ratios (ORs) from the other methods must align in direction with the IVW; otherwise, they are not deemed statistically significant. Moreover, multivariate MR is an extension of univariate MR to jointly detect the causal effects of multiple risk factors (26) and was used to adjust for differences in genetic prediction of green tea consumption, smoking initiation and alcohol consumption (27).

To avoid increasing the risk of Type I errors when performing multiple statistical tests (28), we adjusted the significance level of p < 0.002 (0.05/25) using the Bonferroni correction. *p*-values falling above the Bonferroni-corrected threshold but below the conventional significance level (p < 0.05) were categorized as suggestive of causal associations.

Sensitivity analysis

We conducted a sensitivity analysis employing various methods to ascertain the robustness and validity of the results. Heterogeneity in the study results was assessed using the Cochrane Q-test, where a p-value less than 0.05 indicated the presence of heterogeneity, leading to the utilization of a random effects model; conversely, a p-value greater than 0.05 signified the absence of heterogeneity, prompting the use of a fixed effects model. Additionally, the MR-Egger regression intercept term and the MR-PRESSO method were employed to evaluate the horizontal multivariate validity of instrumental variables, with a significance level of p < 0.05 suggesting the potential existence of horizontal multivariate validity (29). Horizontal pleiotropy occurs when single nucleotide polymorphisms (SNPs) utilized as instrumental variables influence outcomes through pathways other than the intended exposure. MR Egger regression, a method accounting for potential variable heterogeneity, yields a corrected estimate of the causal effect, with the slope obtained representing this

¹ https://www.ebi.ac.uk/gwas/

² https://ldlink.nih.gov/?tab=ldtrait/

estimate (30). The leave-one-out method involves identifying SNP loci that may impact MR results and sequentially removing non-compliant loci to mitigate the influence of specific SNP loci on the outcomes.

All two-sided analyses were conducted using R software (version 4.3.2) and the R packages "TwoSampleMR," "MRPRESSO" and "MVMR."

Results

Univariable MR estimates and sensitivity analyses

For the upper gastrointestinal diseases, as depicted in Figure 2 and Supplementary Table S4, our findings show a suggestive causal relationship between green tea intake and gastroesophageal reflux (OR = 0.9950, 95% CI 0.9900–1.0000, p_{IVW} = 0.047) based on the IVW analysis. However, the analysis of other upper gastrointestinal disorders did not yield statistically significant results (p_{IVW} > 0.05).

For the lower gastrointestinal diseases, as illustrated in Figure 3 and Supplementary Table S4, this study reveals greater green tea intake might suggestively decrease the risk of diverticulosis (OR = 0.9998, 95% CI 0.9996–1.0000, p_{IVW} =0.030), while suggestively increase the risk of Crohn's disease (OR = 1.0001, 95% CI 1.0000–1.0002, p_{IVW} =0.019). However, in the analysis of other lower gastrointestinal diseases, the IVW results did not achieve statistical significance (p_{IVW} >0.05).

For the hepatobiliary and pancreatic diseases, a suggestive negative causal relationship between green tea intake and cholangitis was observed (OR=1.0440, 95% CI 1.0100–1.0790, p_{IVW} =0.011; Figure 4 and Supplementary Table S4). Additionally, our MR analyses revealed no significant association between green tea intake and the other hepatobiliary and pancreatic diseases (p_{IVW} >0.05).

For the acute appendicitis, the primary results of IVW revealed that greater green tea consumption was not significantly associated with the risk of acute appendicitis ($p_{\text{IVW}} > 0.05$; Figure 5 and Supplementary Table S4).

As demonstrated in Figures 6–9, this study presents MR regression slopes and individual causal estimates for green tea intake concerning each SNP locus corresponding to upper gastrointestinal disease, lower gastrointestinal disease, hepatobiliary and pancreatic disease, and acute appendicitis. Supplementary Table S5 reveals that Cochrane *Q*-tests indicated no significant heterogeneity between the investigated outcomes and exposures ($p_{Cochrane Q} > 0.05$), except for heterogeneity observed between green tea intake and alcoholic liver disease ($p_{Cochrane Q} < 0.05$). In cases of heterogeneity, a random-effects model was applied to estimate the MR effect sizes, and no adjustments were deemed necessary for the study results due to heterogeneity. Moreover, the results of the MR-Egger and MR-PRESSO totality tests revealed a symmetric funnel plot (Supplementary Figure S2) and indicated no significant horizontal pleiotropy among any of the examined outcomes and exposures (p > 0.05).

Multivariate MR estimates and sensitivity analyses

After controlling for potential confounders such as smoking and alcohol consumption, multivariate MR analysis showed that greater

green tea consumption in European population was suggestively associated with the decreased risk of oesophagitis (OR = 0.9667, 95% CI: 0.9405–0.9936, p_{IVW} = 0.016) and gastric cancer (OR = 0.9810, 95% CI: 0.9628–0.9996, p_{IVW} = 0.046). Nevertheless, multivariate MR analysis also showed that greater green tea consumption was suggestively associated with the increased risk of Crohn's disease (OR = 1.0001, 95% CI: 1.0000–1.0002, p_{IVW} = 0.007). However, the IVW results showed that green tea intake was not associated with the risk of other gastrointestinal disorders (p_{IVW} > 0.05), as shown in Supplementary Table S6.

In the sensitivity analysis, Cochrane's *Q* test indicated the most MR analyses did not have heterogeneous ($p_{Cochrane Q} > 0.05$). Even in cases where heterogeneity was observed, its impact on our results was small due to our use of the IVW method. Meanwhile, according to the MR-Egger intercept, we found no evidence of horizontal pleiotropy in most association ($p_{intercept} > 0.05$; Supplementary Table S6).

Discussion

Numerous studies have indicated a potential link between green tea consumption and gastrointestinal disorders. However, this association remains incompletely understood. Therefore, the current study employed a two-sample Mendelian randomization approach to elucidate the causal relationship between green tea consumption and these disorders. The IVW analysis revealed green tea consumption was suggestively associated with the decreased risk of oesophagitis and gastric cancer, alongside associated with the increased risk of Crohn's disease. These findings offer valuable dietary insights for both the treatment and prevention of gastrointestinal ailments.

MR has been employed to investigate the association between green tea consumption and gastrointestinal diseases. An MR analysis focused on an East Asian population revealed that increased tea consumption was associated with a reduced risk of gastric cancer (OR = 0.90, 95% CI 0.82–0.99, p=0.037) (31) which is consistent with our findings. However, some studies have reported no significant association between green tea consumption and the risk of gastric cancer (32), likely attributed to differences in the samples used in our study. Future studies will require larger GWAS databases to confirm this relationship.

Gastric cancer (GC) is the fifth most common cancer and the third most common cause of cancer deaths worldwide, and its main risk factors include bacterial infections, dietary influences, and age factors (33). Green tea and its main component, catechins, are believed to have some cancer-preventive effects (34) and are able to exert anticancer functions by inhibiting cell proliferation (35). However, the effect of green tea intake on gastric cancer risk remains a controversial topic. Our results suggest that there may be a negative causal relationship between green tea intake and gastric cancer in upper gastrointestinal diseases. This result is consistent with the conclusion reached in a Mendelian randomization study, which suggested that green tea consumption may be a potential protective factor against gastric cancer (31). However, the results of another review failed to confirm the association between tea consumption and gastric cancer (36). The discrepancy between our findings and those of the aforementioned study may stem from confounding factors and reverse causality present in previous studies, and thus further investigation is needed

Outcomes & Method	ISNP	P.value	UR(95%UI)		Heterogeneity. Fest	WR.EGGER.P	WR.PRESSO.Global.test
Desophagitis				i			
MR Egger	20	0.692	0.9880(0.9330 to 1.0470)		0.687		
Weighted median	20	0.035	0.9550(0.9150 to 0.9970)				
nverse variance weighted	20	0.070	0.9730(0.9440 to 1.0020)	He	0.721	0.537	0.722(raw, 0 outliers)
Simple mode	20	0.111	0.9400(0.8740 to 1.0110)				
Weighted mode	20	0.070	0.9480(0.8970 to 1.0010)				
Hiatus hernia							
MR Egger	13	0.831	1.0000(0.9990 to 1.0000)	•	0.494		
Weighted median	13	0.205	1.0000(0.9990 to 1.0000)	•			
Inverse variance weighted	13	0.054	1.0000(1.0000 to 1.0000)	•	0.527	0.449	0.551(raw, 0 outliers)
Simple mode	13	0.491	1.0000(0.9990 to 1.0000)	•			
Weighted mode	13	0.506	1.0000(0.9990 to 1.0000)	•			
Gastroesophageal reflux							
MR Egger	21	0.242	0.9940(0.9830 to 1.0040)		0.383		
Weighted median	21	0.824	0.9990(0.9920 to 1.0060)	+			
Inverse variance weighted	21	0.047	0.9950(0.9900 to 1.0000)		0.442	0.809	0.473(raw, 0 outliers)
Simple mode	21	0.671	1.0030(0.9910 to 1.0140)				
Weighted mode	21	0.646	1.0030(0.9920 to 1.0130)	+			
Esophageal cancer							
MR Egger	21	0.789	0.9930(0.9460 to 1.0430)		0.756		
Weighted median	21	0.879	0.9970(0.9620 to 1.0340)	HHH I			
Inverse variance weighted	21	0.686	0.9940(0.9670 to 1.0220)	Here and the second sec	0.806	0.961	0.810(raw, 0 outliers)
Simple mode	21	0.903	0.9960(0.9350 to 1.0610)				
Weighted mode	21	0.872	0.9950(0.9350 to 1.0590)				
Gastric ulcer			,				
MR Fager	21	0 102	0.9840(0.9660 to 1.0020)	10	0.994		
Weighted median	21	0.531	0.9960(0.9820 to 1.0090)	-	0.001		
Inverse variance weighted	21	0.198	0.9930(0.9820 to 1.0040)		0.989.0	0 249	0.991(raw, 0.outliers)
Simple mode	21	0.582	0.9940(0.9710 to 1.0160)	1	0.000	0.240	0.001(14W, 0 044(013)
	21	0.002	1,0010(0,9790 to 1,0230)	- E			
	21	0.941	1.0010(0.9790101.0230)	- T			
	20	0.624	0.0040/0.0500 to 1.0100		0.254		
WR Eggel	20	0.034	0.9940(0.9890 to 1.0190)	T	0.354		
vveignied median	20	0.792			0.400	0 700	0.440(
Circula manda	20	0.122	0.9900(0.9770 to 1.0030)		0.409	0.730	0.442(raw, 0 outliers)
Simple mode	20	0.576	0.9920(0.9650 to 1.0200)	Here			
Weighted mode	20	0.888	0.9990(0.9800 to 1.0180)	HEH			
Acute gastritis							
MR Egger	20	0.460	1.0180(0.9720 to 1.0660)		0.368		
Weighted median	20	0.859	1.0030(0.9680 to 1.0390)	H H			
Inverse variance weighted	20	0.143	0.9810(0.9570 to 1.0060)	Hel	0.238	0.084	0.217(raw, 0 outliers)
Simple mode	20	0.087	0.9350(0.8700 to 1.0060)				
Weighted mode	20	0.514	1.0200(0.9620 to 1.0810)	H			
Chronic gastritis							
MR Egger	20	0.752	1.0040(0.9810 to 1.0270)	HH	0.863		
Weighted median	20	0.535	0.9950(0.9790 to 1.0110)	Here is a second se			
nverse variance weighted	20	0.497	0.9960(0.9840 to 1.0080)	+	0.872	0.441	0.895(raw, 0 outliers)
Simple mode	20	0.669	0.9950(0.9740 to 1.0170)	H			
Weighted mode	20	0.775	0.9970(0.9790 to 1.0160)	1411			
Gastric cancer							
MR Egger	21	0.838	0.9950(0.9530 to 1.0400)		0.226		
Weighted median	21	0.022	0.9600(0.9260 to 0.9940)				
Inverse variance weighted	21	0.094	0.9780(0.9520 to 1.0040)	101	0.221	0.327	0.228(raw, 0 outliers)
Simple mode	21	0.138	0.9470(0.8830 to 1.0150)				
Weighted mode	21	0.058	0.9480(0.8990 to 0.9990)				
J					1.05		
			0.75	1	1.25		

FIGURE 2

MR analysis of green tea intake to upper gastrointestinal diseases in the European population. OR, odds ratio; CI, confidence interval; MR, Mendelian randomization.

to confirm the association. In addition, since this study operated at the gene level through SNP loci, there were discrepancies between the observed results and real-world test scenarios. Therefore, although our findings provide potential insights for adjusting the dietary patterns of gastric cancer patients, they need to be interpreted with caution. In order to more clearly define the causal relationship between green tea intake and gastric cancer, future studies require more refined study designs and large-scale epidemiologic investigations. These efforts are essential to establish a reliable understanding of the relationship between green tea intake and gastric cancer.

Inflammation and damage to the mucosa of the esophagus known as oesophagitis is common worldwide and has a major impact on health and quality of life. A variety of physical, chemical and infectious

Juccomes & Methou	ISNP	P.value	OR(95%CI)		Heterogeneity.Test	MR.EGGER.P	MR.PRESSO.Global.test.
ntestinal obstruction				1.1			
MR Egger	17	0.790	1.0000(0.9997 to 1.0002)	•	0.390		
Neighted median	17	0.618	1.0000(0.9998 to 1.0001)	+			
nverse variance weighted	17	0.780	1.0000(0.9999 to 1.0001)	+	0.459	0.876	0.472(raw, 0 outliers)
Simple mode	17	0.508	0.9999(0.9995 to 1.0003)	•			
Neighted mode	17	0.537	0.9999(0.9995 to 1.0002)	÷.			
rritable bowel disease							
MR Egger	20	0.733	1.0044(0.9796 to 1.0299)	HHH .	0.346		
Neighted median	20	0.564	0.9950(0.9780 to 1.0122)	H			
nverse variance weighted	20	0.983	0.9999(0.9873 to 1.0126)		0.397	0.681	0.400(raw, 0 outliers)
Simple mode	20	0.584	0.9923(0.9655 to 1.0197)	H			
Neighted mode	20	0.532	0.9935(0.9737 to 1.0137)	141			
Diverticular disease							
MR Egger	13	0.367	0.9998(0.9995 to 1.0002)	+	0.512		
Neighted median	13	0.044	0.9998(0.9995 to 1.0000)	÷			
nverse variance weighted	13	0.030	0.9998(0.9996 to 1.0000)		0.597	0.926	0.621(raw, 0 outliers)
Simple mode	13	0.174	0.9997(0.9993 to 1.0001)				
Neighted mode	13	0.141	0.9997(0.9993 to 1.0001)	+			
Crohn's disease							
MR Egger	20	0.175	1.0001(1.0000 to 1.0002)		0.621		
Neighted median	20	0.169	1.0001(1.0000 to 1.0002)				
nverse variance weighted	20	0.019	1.0001(1.0000 to 1.0002)	+	0.680	0.809	0.686(raw, 0 outliers)
Simple mode	20	0.528	1.0001(0.9999 to 1.0003)	÷			
Neighted mode	20	0.552	1.0001(0.9999 to 1.0002)				
JIcerative colitis			,				
VR Egger	21	0.284	0.9858(0.9612 to 1.0112)	Here a	0.250		
Neighted median	21	0.683	1.0037(0.9862 to 1.0215)				
nverse variance weighted	21	0.967	0.9997(0.9865 to 1.0131)		0.216	0.222	0.181(raw, 0 outliers)
Simple mode	21	0.710	1.0067(0.9724 to 1.0421)	HPH I			
Neighted mode	21	0.718	1.0067(0.9714 to 1.0432)				
Colorectal cancer			,				
MR Egger	21	0.325	0.9901(0.9711 to 1.0094)	HER	0.884		
Neighted median	21	0.742	0.9976(0.9831 to 1.0122)	191			
nverse variance weighted	21	0.341	0.9947(0.9839 to 1.0056)	4	0.903	0.574	0.909(raw, 0 outliers)
Simple mode	21	0.994	1.0001(0.9747 to 1.0261)	H			(,, ,
Neighted mode	21	0.994	1.0001(0.9752 to 1.0257)				
	-				1.05		
			0.75	1	1.25		

FIGURE 3

MR analysis of green tea intake to lower gastrointestinal diseases in the European population. OR, odds ratio; CI, confidence interval; MR, Mendelian randomization.

agents can cause oesophagitis (37). Although studies exploring the correlation between green tea consumption and oesophagitis were lacking within our search, we delved into this relationship through a two-sample MR analysis. Our study revealed a suggestive causal relationship between green tea intake and oesophagitis. Thus, our exploration of the relationship between green tea consumption and oesophagitis could provide valuable insights into nutritional recommendations and disease management, potentially enhancing clinical approaches to managing this disease.

Epidemiological studies present conflicting findings regarding the correlation between beverage consumption, including green tea intake, and the risk of Crohn's disease (14). Among dietary investigations in the clinical realm of Crohn's disease, analyses concentrating on individual nutrients or foods prevail. The stimulative impact of green tea's caffeine content on gastrointestinal motility could potentially exacerbate Crohn's disease symptoms by elevating bowel movement frequency (8). Our findings uncovered a potential positive causal link between tea intake and Crohn's disease. The outcomes of a Mendelian analysis suggest that genetically induced exposure to tea intake elevates the susceptibility to Crohn's disease (38). Nevertheless, contrasting findings emerged from another meta-analysis, indicating

a negative correlation between tea intake and Crohn's disease risk (14). However, some studies have failed to yield significant evidence supporting an association between tea intake and Crohn's disease (13). Hence, there could be merit in instituting surveillance and preventive measures for Crohn's disease within populations exhibiting heightened tea intake.

We also investigated the association between green tea intake and other gastrointestinal disorders. However, the results of our two-sample Mendelian randomization analysis indicated no significant relationship ($p_{IVW} > 0.05$). Furthermore, in a sizable community-based prospective cohort study, green tea consumption did not correlate with the risk of gastric cancer (39). Moreover, substantial evidence supporting an association between tea intake and ulcerative colitis or non-alcoholic fatty liver disease is reportedly lacking (13). Additionally, one study found no overall significant association between green tea consumption and the risk of colorectal cancer (40). The outcomes of another prospective cohort study's metaanalysis similarly indicated no significant impact of tea consumption on colorectal cancer risk among both men and women (41). Nevertheless, several studies diverge from our findings. Green tea has been identified as a protective agent against gastric cancer (15, 42) and

Outcomes & Method	nSNP	P.value	OR(95%CI)		Heterogeneity.Test	MR.EGGER.P	MR.PRESSO.Global.test.P
Non-alcoholic fatty liver disease				i			
MR Egger	13	0.136	0.9720(0.9400 to 1.0060)	He I	0.631		
Weighted median	13	0.885	0.9980(0.9760 to 1.0210)	HH .			
nverse variance weighted	13	0.612	0.9960(0.9800 to 1.0120)	6 6 6	0.502	0.149	0.534(raw, 0 outliers)
Simple mode	13	0.998	1.0000(0.9630 to 1.0390)	HHH			
Weighted mode	13	0.987	1.0000(0.9630 to 1.0400)	H H H			
Alcoholic liver disease							
MR Egger	20	0.934	0.9980(0.9440 to 1.0550)		0.026		
Weighted median	20	0.447	1.0130(0.9810 to 1.0460)	HeH			
Inverse variance weighted	20	0.446	1.0110(0.9830 to 1.0400)	Here a	0.032	0.585	0.059(raw, 0 outliers)
Simple mode	20	0.451	1.0190(0.9710 to 1.0710)				
Weighted mode	20	0.470	1.0130(0.9790 to 1.0490)	He-I			
Cirrhosis							
MR Egger	20	0.610	0.9720(0.8730 to 1.0820)		0.627		
Weighted median	20	0.125	1.0720(0.9810 to 1.1710)				
Inverse variance weighted	20	0.230	1.0370(0.9780 to 1.0990)		0.557	0.176	0.506(raw, 0 outliers)
Simple mode	20	0.352	0.9130(0.7560 to 1.1010)				
Weighted mode	20	0.128	1.0720(0.9840 to 1.1670)				
Cholangitis							
MR Eager	8	0.906	0.9960(0.9350 to 1.0610)		0.729		
Weighted median	8	0.268	1 0260(0 9800 to 1 0740)				
Inverse variance weighted	8	0.011	1.0440(1.0100 to 1.0790)		0.483	0 140	0.493(raw_0.outliers)
Simple mode	8	0.664	1.0160(0.9470 to 1.0910)		0.400	0.140	0.400(14W, 0 0441010)
	8	0.676	1.0160(0.9450 to 1.0940)				
	0	0.070	1.0100(0.9400 10 1.0940)				
MR Eggor	20	0.650	0.0070/0.0840 to 1.0100)	1	0.650		
Mainhead median	20	0.009			0.050		
	20	0.102	0.9990(0.9900 to 1.0090)	I	0.607	0.644	0.672(row 0.outliora)
	20	0.102		1	0.097	0.044	0.072(raw, 0 outliers)
	20	0.044		1			
vveighted mode	20	0.798	1.0010(0.9900 to 1.0130)	- T			
		0.040	0.0070/0.0000 / . 4.0400	1	0.554		
MR Egger	20	0.616	0.9970(0.9830 to 1.0100)		0.551		
VVeighted median	20	0.463	0.9960(0.9870 to 1.0060)	1			
Inverse variance weighted	20	0.108	0.9940(0.9880 to 1.0010)		0.607	0.709	0.588(raw, 0 outliers)
Simple mode	20	0.181	0.9880(0.9720 to 1.0050)	101			
Weighted mode	20	0.814	1.0010(0.9900 to 1.0130)				
Acute pancreatitis				1			
MR Egger	20	0.914	0.9980(0.9690 to 1.0280)	H	0.856		
Weighted median	20	0.856	1.0020(0.9810 to 1.0240)	Her			
nverse variance weighted	20	0.242	0.9910(0.9760 to 1.0060)	101	0.878	0.568	0.868(raw, 0 outliers)
Simple mode	20	0.682	0.9930(0.9590 to 1.0280)	H			
Weighted mode	20	0.727	1.0040(0.9830 to 1.0260)	H H H			
Chronic pancreatitis							
MR Egger	20	0.792	1.0060(0.9630 to 1.0510)		0.166		
Weighted median	20	0.615	1.0070(0.9790 to 1.0360)	Here			
Inverse variance weighted	20	0.841	1.0020(0.9800 to 1.0250)	H H H	0.206	0.848	0.239(raw, 0 outliers)
Simple mode	20	0.399	1.0190(0.9760 to 1.0650)				
Weighted mode	20	0.557	1.0100(0.9780 to 1.0420)	HPH .			
Pancreatic cancer							
MR Egger	21	0.184	0.9680(0.9230 to 1.0140)		0.905		
Weighted median	21	0.695	0.9930(0.9610 to 1.0270)	HH			
Inverse variance weighted	21	0.637	0.9940(0.9690 to 1.0190)	H	0.864	0.198	0.863(raw, 0 outliers)
Simple mode	21	0.983	1.0010(0.9440 to 1.0610)		1007717171		
Weighted mode	21	0.982	1.0010(0.9450 to 1.0590)				
			0.75	1 1	1.25		
			<i>.</i>				

MR analysis of green tea intake to hepatobiliary and pancreatic diseases in the European population. OR, odds ratio; CI, confidence interval; MR, Mendelian randomization.

colorectal cancer (16, 43). Moreover, in a large prospective cohort study, moderate tea consumption (0.5–1 cup/day) correlated with a reduced risk of irritable bowel syndrome (44). Additionally, a case-control study revealed that frequent tea consumption was associated with decreased odds of ulcerative colitis, even after adjusting for age, sex, body mass index, and smoking history (45). Furthermore, A small increase in the intake of flavan-3-ol-rich foods (e.g., green tea) may help improve the survival of colorectal cancer patients (46). The

reason this is different from our findings may be that we limited the type of tea ingested to green tea, and thus our results do not make sense. Alternatively, it could be attributed to heterogeneity between the studies, warranting further experimental design to elucidate the relationship.

The relationship between green tea and gastrointestinal disorders can be explained by a variety of biological mechanisms. Chalazonitis et al. (47) showed that brain dopamine neurotrophic factor is





essential for the development, maintenance and gastrointestinal transit regulation of intestinal neurons, which is in line with the results of the present study. In lower gastrointestinal diseases, for colitis, a study by Belle et al. (48) demonstrated that TFF3 interacts with LINGO2 to regulate EGFR activation and is able to prevent colitis. For colon cancer, a study by Aljahdali et al. (49) found a strong association between IPO11 downregulation and poorer colon cancer patient survival. And the co-expression gene profile of IPO11 was similarly associated with colon carcinogenesis. Similarly, Yang et al. (50) showed that FITM2 in colon adenocarcinoma has been shown to be a key mRNA. a study by D'Ermo et al. (51) showed that

pathogenic mutations in the PTEN oncogene lead to continuous involvement of the gastrointestinal tract and eventually to the development of diseases such as colorectal cancer. In hepatobiliary and pancreatic diseases, for nonalcoholic fatty liver disease, Li et al. (52) found that vascular endothelial growth factor B (VEGFB) has the potential to regulate lipid metabolism and plays a regulatory role in the development and progression of NAFLD. For pancreatic cancer, Rizzato et al. (53) showed that the CTNNA2 gene was associated with survival in patients with pancreatic ductal adenocarcinoma. These studies support our results, as the above genes are the nearest gene of SNPs associated with green tea intake.



FIGURE 7

Scatter plot of SNPs associated with green tea intake on lower gastrointestinal diseases. (A) Intestinal obstruction. (B) Irritable bowel disease. (C) Diverticular disease. (D) Crohn's disease. (E) Ulcerative colitis. (F) Colorectal cancer.



Scatter plot of SNPs associated with green tea intake on hepatobiliary and pancreatic diseases. (A) Non-alcoholic fatty liver disease. (B) Alcoholic liver disease. (C) Cirrhosis. (D) Cholangitis. (E) Cholecystitis. (F) Cholelithiasis. (G) Acute pancreatitis. (H) Chronic pancreatitis. (I) Pancreatic cancer.



Ohishi et al. (54) showed that green tea and EGCG inhibited gene expression of inflammation-related enzymes and had beneficial effects on inflammatory diseases. Since green tea and EGCG have multiple targets and act as anti-inflammatory agents in a pleiotropic manner, including acting as an antioxidant scavenging mechanism for reactive oxygen species, leading to attenuation of nuclear factor-kB activity. A study by Kim et al. (55) showed that a combined extract of Artemisia absinthium and green tea (MPGT) had significant antioxidant or antiinflammatory effects on Helicobacter pylori-associated gastropathy. Among them, the significant protective changes in alcoholic gastritis with MPGT were associated with increased expression of cytoprotective genes such as heat shock protein (HSP) 27, HSP60 and PDGF, and significant reduction in the levels of calcium-dependent phospholipase A2, MAPK and NF-KB. Therefore, we may consider the use of EGCG-rich green tea to improve the quality of life of patients with gastrointestinal diseases (56).

This study boasts several strengths. Firstly, to our knowledge, our study is the first comprehensive exploration of the causal relationship between green tea intake and various gastrointestinal disorders, including upper gastrointestinal diseases, lower gastrointestinal diseases, hepatobiliary and pancreatic diseases, and acute appendicitis. Second, it delves into the correlation between green tea intake and gastrointestinal diseases at a genetic level, thereby mitigating confounding factors and biases, thus significantly bolstering the precision and credibility of the findings. Secondly, the study employs chained unbalanced clustering, heterogeneity detection, horizontal pleiotropy detection, and leave-one-out techniques to conduct a sensitivity analysis of the data, further solidifying the stability of the causal relationship.

Nonetheless, this study is not without its limitations, which could account for the variance between its findings and those of existing literature. Firstly, this study focuses on the European population; however, green tea consumption in Europe is relatively low. According to the Tea Council of Great Britain, black tea imports into the UK in 2023 will be £226 million and green tea imports will be £22.62 million. Thus limiting the generalizability of the results of this study. Second, the study included only 122 cirrhosis patients, which may affect the robustness of the conclusions drawn. Thirdly, our pooled data on green tea consumption were obtained from the UK Biobank database with data from 24-h dietary recalls, which may be subject to recall bias to the extent of attenuating the true association, and there is a lack of SNP data on green tea frequency, the exposure variable in this study may not be representative of green tea intake in the long term. Fourthly, the exposure data and partial outcome data were obtained from the UKB database, potentially introducing bias due to sample overlap. Fifthly, we utilized the LDtrait tool to find the SNP identified in our study were confounders, which utilizes GWAS summary statistics gathered from the GWAS Catalog, which may result in the searches may not be comprehensive. Consequently, future research endeavors should strive to address these issues to attain a more comprehensive understanding of the relationship between green tea intake and gastrointestinal disorders.

Conclusion

Our two-sample MR analysis suggests greater green tea consumption was suggestively associated with the decreased risk of oesophagitis and gastric cancer, while greater green tea consumption in was suggestively associated with the increased risk of Crohn's disease. Moreover, larger GWAS databases will be needed in the future to confirm this relationship to ensure the robustness and reliability of the study results.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

CC: Formal analysis, Writing – original draft. YL: Validation, Writing – review & editing. JX: Writing – review & editing. QC: Conceptualization, Data curation, Formal analysis, Methodology, Writing – review & editing. JH: Conceptualization, Formal analysis, Methodology, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

The authors are grateful to the participants of all the GWASs used in this manuscript and the investigators who made these GWAS data publicly available. The authors thank Ph.D. candidate Yiming Hu from

References

1. Edgington-Mitchell LE. Pathophysiological roles of proteases in gastrointestinal disease. *Am J Physiol Gastrointest Liver Physiol.* (2016) 310:G234–9. doi: 10.1152/ajpgi.00393.2015

2. Michelfelder AJ, Lee KC, Bading EM. Integrative medicine and gastrointestinal disease. *Prim Care*. (2010) 37:255–67. doi: 10.1016/j.pop.2010.02.003

3. Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. *Gastroenterology*. (2022) 162:621–44. doi: 10.1053/j.gastro.2021.10.017

 Cao H, Huang X, Zhi X, Han C, Li L, Li Y. Association between tea consumption and gastroesophageal reflux disease: a meta-analysis. *Medicine*. (2019) 98:e14173. doi: 10.1097/MD.000000000014173

5. Chen Y, Chen C, Ouyang Z, Duan C, Liu J, Hou X, et al. Prevalence and beveragerelated risk factors of gastroesophageal reflux disease: an original study in Chinese college freshmen, a systemic review and meta-analysis. *Neurogastroenterol Motil*. (2022) 34:e14266. doi: 10.1111/nmo.14266

6. Delveus H, Lanzing G, Sahli H, Rönnow CF, Dahlbäck C, Buchwald P. Diverticulosis and risk of diverticulitis in 10 years; a Swedish retrospective observational study. *Scand J Gastroenterol.* (2024) 59:433–6. doi: 10.1080/00365521.2023.2301345

7. Carabotti M, Falangone F, Cuomo R, Annibale B. Role of dietary habits in the prevention of diverticular disease complications: a systematic review. *Nutrients*. (2021) 13:1288. doi: 10.3390/nu13041288

8. de Castro MM, Corona LP, Pascoal LB, Miyamoto JÉ, Ignacio-Souza LM, de Lourdes Setsuko Ayrizono M, et al. Dietary patterns associated to clinical aspects in Crohn's disease patients. *Sci Rep.* (2020) 10:7033. doi: 10.1038/ s41598-020-64024-1

9. O'Keefe SJ. Nutrition and gastrointestinal disease. *Scand J Gastroenterol Suppl.* (1996) 31:52–9. doi: 10.3109/00365529609094750

10. Ely R, Long B, Koyfman A. The emergency medicine-focused review of cholangitis. *J Emerg Med.* (2018) 54:64–72. doi: 10.1016/j.jemermed.2017.06.039

11. Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, et al. Green tea (*Camellia sinensis*) for the prevention of cancer. *Cochrane Database Syst Rev.* (2020) 3:CD005004. doi: 10.1002/14651858.CD005004

12. Fan FY, Sang LX, Jiang M. Catechins and their therapeutic benefits to inflammatory bowel disease. *Molecules*. (2017) 22:484. doi: 10.3390/molecules22030484

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention for statistics consultation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024.1426779/ full#supplementary-material

13. Sun Q, Gao N, Song J, Jia J, Dong A, Xia W. The association between tea consumption and non-malignant digestive system diseases: a Mendelian randomized study. *Clin Nutr ESPEN*. (2024) 60:327–32. doi: 10.1016/j.clnesp.2024.02.012

14. Yang Y, Xiang L, He J. Beverage intake and risk of Crohn disease: a meta-analysis of 16 epidemiological studies. *Medicine*. (2019) 98:e15795. doi: 10.1097/MD.000000000015795

15. Huang Y, Chen H, Zhou L, Li G, Yi D, Zhang Y, et al. Association between green tea intake and risk of gastric cancer: a systematic review and dose-response metaanalysis of observational studies. *Public Health Nutr.* (2017) 20:3183–92. doi: 10.1017/ \$1368980017002208

16. Kim H, Lee J, Oh JH, Chang HJ, Sohn DK, Shin A, et al. Protective effect of green tea consumption on colorectal cancer varies by lifestyle factors. *Nutrients*. (2019) 11:2612. doi: 10.3390/nu11112612

17. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med.* (2008) 27:1133–63. doi: 10.1002/sim.3034

18. Dönertaş HM, Fabian DK, Valenzuela MF, Partridge L, Thornton JM. Common genetic associations between age-related diseases. *Nat Aging.* (2021) 1:400–12. doi: 10.1038/s43587-021-00051-5

19. Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, et al. Genome-wide association study of NAFLD using electronic health records. *Hepatol Commun.* (2022) 6:297–308. doi: 10.1002/hep4.1805

 Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A crosspopulation atlas of genetic associations for 220 human phenotypes. *Nat Genet*. (2021) 53:1415–24. doi: 10.1038/s41588-021-00931-x

21. Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. *Nat Genet.* (2017) 49:269–73. doi: 10.1038/ng.3745

22. Lin SH, Brown DW, Machiela MJ. LDtrait: an online tool for identifying published phenotype associations in linkage disequilibrium. *Cancer Res.* (2020) 80:3443–6. doi: 10.1158/0008-5472.CAN-20-0985

23. Stephen B, Adam B, Thompson Simon G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* (2013) 37:658–65. doi: 10.1002/gepi.21758

24. Young LJ, Antwi-Boasiako S, Ferrall J, Wold LE, Mohler PJ, El Refaey M. Genetic and non-genetic risk factors associated with atrial fibrillation. *Life Sci.* (2022) 299:120529. doi: 10.1016/j.lfs.2022.120529

25. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. *Circ Res.* (2020) 127:4–20. doi: 10.1161/CIRCRESAHA.120.316340

26. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *Am J Epidemiol.* (2015) 181:251–60. doi: 10.1093/aje/kwu283

27. Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet.* (2019) 51:237–44. doi: 10.1038/s41588-018-0307-5

28. Armstrong RA. When to use the Bonferroni correction. *Ophthalmic Physiol Opt.* (2014) 34:502–8. doi: 10.1111/opo.12131

29. Kindblom JM, Bygdell M, Sondén A, Célind J, Rosengren A, Ohlsson C. BMI change during puberty and the risk of heart failure. *J Intern Med.* (2018) 283:558–67. doi: 10.1111/joim.12741

30. Jack B, George DS, Stephen B. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* (2015) 44:512–25. doi: 10.1093/ije/dyv080

31. Tan Y, Wei Z, Liu K, Qin Y, Hui W. Lifestyle habits and gastric cancer in an East Asian population: a Mendelian randomization study. *Front Oncol.* (2023) 13:1224753. doi: 10.3389/fonc.2023.1224753

32. Nie D, He X, Zheng H, Deng D, He F, Li R, et al. Association between green tea intake and digestive system cancer risk in European and East Asian populations: a Mendelian randomization study. *Eur J Nutr.* (2024) 63:1103–11. doi: 10.1007/s00394-023-03312-8

33. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. (2020) 396:635–48. doi: 10.1016/S0140-6736(20)31288-5

34. Chen D, Daniel KG, Kuhn DJ, Kazi A, Bhuiyan M, Li L, et al. Green tea and tea polyphenols in cancer prevention. *Front Biosci*. (2004) 9:2618–31. doi: 10.2741/1421

35. Hazafa A, Rehman KU, Jahan N, Jabeen Z. The role of polyphenol (flavonoids) compounds in the treatment of cancer cells. *Nutr Cancer*. (2020) 72:386–97. doi: 10.1080/01635581.2019.1637006

36. Hou IC, Amarnani S, Chong MT, Bishayee A. Green tea and the risk of gastric cancer: epidemiological evidence. *World J Gastroenterol.* (2013) 19:3713–22. doi: 10.3748/wjg.v19.i24.3713

37. Maguire A, Sheahan K. Pathology of oesophagitis. *Histopathology*. (2012) 60:864–79. doi: 10.1111/j.1365-2559.2011.03855.x

38. Saadh MJ, Pal RS, Arias-Gonzáles JL, Orosco Gavilán JC, Jc D, Mohany M, et al. A Mendelian randomization analysis investigates causal associations between inflammatory bowel diseases and variable risk factors. *Nutrients*. (2023) 15:1202. doi: 10.3390/nu15051202

39. Sheerah H, Keyang L, Eshak ES, Cui R, Shirai K, Muraki I, et al. Association of tea consumption and the risk of gastric cancer in Japanese adults: the Japan Collaborative Cohort Study. *BMJ Open.* (2020) 10:e038243. doi: 10.1136/bmjopen-2020-038243

40. Wada K, Oba S, Tsuji M, Goto Y, Mizuta F, Koda S, et al. Green tea intake and colorectal cancer risk in Japan: the Takayama study. *Jpn J Clin Oncol.* (2019) 49:515–20. doi: 10.1093/jjco/hyz030

41. Zhu MZ, Lu DM, Ouyang J, Zhou F, Huang PF, Gu BZ, et al. Tea consumption and colorectal cancer risk: a meta-analysis of prospective cohort studies. *Eur J Nutr.* (2020) 59:3603–15. doi: 10.1007/s00394-020-02195-3

42. Poorolajal J, Moradi L, Mohammadi Y, Cheraghi Z, Gohari-Ensaf F. Risk factors for stomach cancer: a systematic review and meta-analysis. *Epidemiol Health.* (2020) 42:e2020004. doi: 10.4178/epih.e2020004

43. Kumar A, Chinnathambi S, Kumar M, Pandian GN. Food intake and colorectal cancer. *Nutr Cancer*. (2023) 75:1710–42. doi: 10.1080/01635581.2023.2242103

44. Wu S, Yang Z, Yuan C, Liu S, Zhang Q, Zhang S, et al. Coffee and tea intake with long-term risk of irritable bowel syndrome: a large-scale prospective cohort study. *Int J Epidemiol.* (2023) 52:1459–72. doi: 10.1093/ije/dyad024

45. Almofarreh A, Sheerah HA, Arafa A, Ahamed SS, Alzeer O, Al-Hunaishi W, et al. Beverage consumption and ulcerative colitis: a case-control study from Saudi Arabia. *Int J Environ Res Public Health*. (2022) 19:2287. doi: 10.3390/ijerph19042287

46. Shi S, Wang K, Zhong R, Cassidy A, Rimm EB, Nimptsch K, et al. Flavonoid intake and survival after diagnosis of colorectal cancer: a prospective study in 2 US cohorts. *Am J Clin Nutr.* (2023) 117:1121–9. doi: 10.1016/j.ajcnut.2023.03.026

47. Chalazonitis A, Li Z, Pham TD, Chen J, Rao M, Lindholm P, et al. Cerebral dopamine neurotrophic factor is essential for enteric neuronal development, maintenance, and regulation of gastrointestinal transit. *J Comp Neurol.* (2020) 528:2420-44. doi: 10.1002/cne.24901

48. Belle NM, Ji Y, Herbine K, Wei Y, Park JH, Zullo K, et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. *Nat Commun.* (2019) 10:4408. doi: 10.1038/s41467-019-12315-1

49. Aljahdali MO, Molla MHR. Multi-omics prognostic signatures of IPO11 mRNA expression and clinical outcomes in colorectal cancer using bioinformatics approaches. *Health Inf Sci Syst.* (2023) 11:57. doi: 10.1007/s13755-023-00259-2

50. Yang L, Li L, Ma J, Yang S, Zou C, Yu X. miRNA and mRNA integration network construction reveals novel key regulators in left-sided and right-sided colon adenocarcinoma. *Biomed Res Int.* (2019) 2019:7149296. doi: 10.1155/2019/7149296

51. D'Ermo G, Genuardi M. Gastrointestinal manifestations in PTEN hamartoma tumor syndrome. *Best Pract Res Clin Gastroenterol.* (2022) 58–59:101792. doi: 10.1016/j. bpg.2022.101792

52. Li YQ, Xin L, Zhao YC, Li SQ, Li YN. Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value. *World J Hepatol.* (2023) 15:786–96. doi: 10.4254/wjh.v15.i6.786

53. Rizzato C, Campa D, Talar-Wojnarowska R, Halloran C, Kupcinskas J, Butturini G, et al. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. *Carcinogenesis*. (2016) 37:957–64. doi: 10.1093/carcin/bgw080

54. Ohishi T, Goto S, Monira P, Isemura M, Nakamura Y. Anti-inflammatory action of green tea. *Antiinflamm Antiallergy Agents Med Chem.* (2016) 15:74–90. doi: 10.217 4/1871523015666160915154443

55. Kim YS, Jeong M, Han YM, Park JM, Kwon SO, Hong SP, et al. Combined extracts of artemisia and green tea, mitigated alcoholic gastritis via enhanced heat-shock protein 27. *Korean J Gastroenterol.* (2018) 71:132–42. doi: 10.4166/kjg.2018.71.3.132

56. Diwan B, Sharma R. Green tea EGCG effectively alleviates experimental colitis in middle-aged male mice by attenuating multiple aspects of oxi-inflammatory stress and cell cycle deregulation. *Biogerontology*. (2022) 23:789–807. doi: 10.1007/s10522-022-09976-9